The regulation of medical drugs and devices involves competing goals of assuring safety and efficacy while providing rapid movement of innovative therapies through the investigative and regulatory processes as quickly as possible.
Controversy persists about the differences in U.S. and EU regulatory processes, costs, and the time it can take for a DAD to proceed from concept to approval under the regulations of each. A frequently held assertion is that slower FDA approval processes deprive American citizens of effective DADs that are available to Europeans (2) , and critics have characterized FDA processes as "slow, risk averse, and expensive" (3) . However, the Institute of Medicine determined that current FDA pre-marketing procedures for medical devices are insufficient to assure device safety, particularly those approved largely on their similarity to previously cleared "predicate" devices, rather than on prospective, randomized clinical trials (4) . In the EU, concerns abound that DADs may be approved too quickly, to the detriment of patient safety. In recent years, there have been calls to tighten approval processes and to establish regulatory consistency between the FDA and the EU. Efforts include recent legislation in the U.S. Congress to facilitate release in the United States of drugs that have already achieved European approval (5) . Proposed changes to regulations of the European Commission (EC) regarding device approval are under discussion (6) , but are vigorously opposed by both industry and patient groups insisting that it will impede availability of innovative therapies to the public. States (7, 8) . This review compares European processes with those of the FDA, and discusses some of the challenges facing each.
BACKGROUND
The FDA was an outgrowth of a division of the U.S. Patent Office in the mid-19th century, initially charged with ensuring that medications on the public market were effective as advertised. The Federal Food, Drug and Cosmetics Act of 1938 subsequently invested the agency with more rigorous powers to ensure that drugs were not only effective, but "safe" (9) , and the FDA was ultimately given authority to regulate medical devices in 1976 (10) through legislation that was later amended in the 
EUROPEAN REGULATION OF DRUGS
Efforts to standardize European regulations regarding drug approval first came to fruition before the formation of the EU, with the passage of EC Directive 65/65/EEC in 1965 (12) . The directive defined a medical product as "any substance or combination of substances which may be administered to human beings or animals with a view to making a medical diagnosis or to restoring, correcting, or modifying physiological functions in human beings or in animals." Under the directive, any medicinal product marketed in the member states would first pass approval in the originating state (1, 12, 13) . The directive established consistent guidelines throughout the member states regarding the information that must be submitted for approval: these items parallel regulations of the FDA regarding investigational new drug applications and new drug approval applications. The drug then progresses through sequential studies analogous to those in the United States: Phase I trials conducted in a small number of healthy subjects to clarify pharmacology and dose range, Phase II trials conducted in several hundred patients with the target condition to investigate the dose-response relationship, and Phase III confirmatory trials in several hundred to several thousand patients to substantiate safety and efficacy. As in the United States, the EC provides means for approving "orphan drugs," or those that treat conditions that affect so few people that randomized controlled trials may be impossible to complete (16, 17) . There are also methods for obtaining conditional approval for drugs to be used in emergency conditions, or other conditional approvals (18).
The European Medicines Agency (EMA) was formed in 1995 with funding from the EU, pharmaceutical industry, and member states (19). The EMA was charged with harmonizing processes in the member state regulatory agencies to reduce annual costs to drug companies (that previously were required to obtain separate approvals in each member state) as well as to eliminate competition-restricting regulation in sovereign states. However, the EMA does not oversee all drug approvals the way the FDA does in the United States. In Europe, there are 4 routes by which a drug can be approved, depending on the drug class and manufacturer preference (6 (20) .
Another determinant of the concept to market period is the time it takes the regulatory agencies to conduct their reviews. It is commonly asserted that FDA processes are significantly slower than those of the EMA, and that FDA processes should be loosened to facilitate drug approval and equalize drug availability in Europe and the United States. Closer examination shows that, in fact, drug review times are significantly shorter at the FDA than the EMA. One study demonstrated that for similar drugs, the median times of initial reviews were 303 and 366 days, respectively, and for full reviews was 322 days compared with 366 days, respectively (21 TRANSPARENCY OF DRUG APPROVAL DATA. Not all data generated for drug approval is ultimately submitted for peer review and publication, and this can be a significant source of publication bias (23) .
Transparency of trial data is an issue for both the FDA and EMA, which poses challenges to the production of systematic reviews and meta-analyses that may be critical to public safety and health. At the FDA, nonpublished data included in new drug applications is available for review online (24) and by request.
MacLean et al. (25) found the methodological quality of these studies generally comparable to that of published trials, and confirm they can be invaluable in systematic reviews. In contrast to the FDA, at the EMA, nonpublished data is considered "commercially sensitive" and not available to the public unless there is an overriding public interest. Gøtzsche and Jørgensen (26) detailed their years-long struggle to obtain unpublished trial data from the EMA in 2011.
EUROPEAN REGULATION OF DEVICES
Approval processes for medical devices also followed a path of "harmonization" in Europe with establishment of the EU, but medical device regulation also does not fall solely to any one agency.
Three EC directives that have been subject to pe- In the EU, every marketed medical device must carry a Conformité Européenne (CE) mark indicating that it conforms to relevant directives set forth in the EC Medical Device Directives of the EU. A device with a CE mark can be marketed in any EU member state.
Medical devices that are non-implantable and considered low risk are "self-marked," meaning that the manufacturer itself simply certifies compliance
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Through a complex system of legislation, high-risk medical device approval applications can be filed in any member state and reviewed by a "Notified Body" (NB) established within that state and authorized by that state's Competent Authority, or health agency, to assess and assure conformity with requirements of the relevant EC directive (27) . NBs are private companies that contract with manufacturers to supply these certifications for a fee, and there are currently around 76 NBs in the EU. Once the NB agrees that the device meets requirements for conformity, the NB issues a CE mark, and the device can then be marketed in EU member states (31) .
Until recently, the CE mark authorized marketing "without further controls and no further evaluation" The FDA was established as a central answer to the problem of the increasing marketing of health products for which benefits were unproven, nonexistent, or minimal, and products that were frankly harmful (7) . By contrast, the European system of NBs was developed out of initiatives to foster innovation and commercial and industrial policies in Europe, and not as a public health or consumer protection agency. 
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Before approval of a medical device in the United
States, a device must not only be shown to be safe,
but efficacious (3). Medical devices approved in
Europe need only to demonstrate safety and performance, that is, that they perform or, in the case devices approved based on predicates rather than clinical trials, will probably perform as designed and that potential benefits outweigh potential risks. They
are not required to demonstrate clinical efficacy. A collateral effect of more "commercially sensitive" regulations in Europe is that initial approval of U.S. company-backed devices is increasingly being sought in the EU before application in the United States (40) .
Another challenge for EU processes is that, whereas only 1 organization (the FDA) oversees medical device development and approval in the United States, a complex mesh of organizations with various The FDA processes for device approvals are centralized within 1 agency, but allow device approvals based on clinical trials, or based on predicate devices.
European processes for device approval follow decentralized paths in each of the member states and also allow for approval based on predicate devices. CE ¼ Conformité Européenne; NB ¼ Notifying Body; other abbreviations as in Figure 1 .
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A U G U S T 2 0 1 6 : 3 9 9 -4 1 2 allegiances are responsible for oversight in the EUincluding government agencies (Competent Authorities) and private, for-profit companies (NBs). In the United States, the single authority system presumably allows for better coordination and enforcement, but may result in a less flexible, lengthy, and expensive process (30) . The EU process, by contrast, may provide more flexibility and more rapid approval of devices, but its rules are more difficult to define and enforce. In addition, approval does not equate with availability to patients. Analysis shows that although time for regulatory reviews may be longer in the United States, the timeline from application to clinical 
CONTINUING CHALLENGES TO DRUG AND DEVICE REGULATION AND APPROVAL
The EU and United States face some common challenges in balancing the mandate to ensure DAD safety and efficacy against the pressure from industry and the public to expedite the transit of new DADs to market.
SAFETY AND EFFICACY EVIDENCE REQUIREMENTS.
Appropriate and effective evidentiary requirements for device approval is a serious problem for both the Approximately 71% of devices in 1 study had been cleared through the less rigorous 501(k) process, and another 7% were exempted entirely from review (53).
These statistics do not begin to address quality issues plaguing product applications, which the FDA itself has determined to occur in more than one-half of submissions (54) . 
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States without ever having been tested in humans.
Such was the case with the DePuy ASR LX Acetabular
Cup System, a metal-on-metal hip replacement product that later suffered an unacceptable high rate of failure and was recalled (8) .
In (58) . This raises the risk that a device will be approved that offers no substantial advantages or benefits over existing products, or else that the general public will be exposed to serious adverse effects that were not detected in limited clinical experience. 
POST-MARKET SAFETY AND EFFICACY SURVEILLANCE.
In the United States, physicians, manufacturers, and patients have the ability to report adverse events involving DADs to the FDA, which centrally collects and reviews adverse event data. The FDA has the power to condition approval of DADs on the completion of post-marketing studies, and may even determine what the design of such studies should be.
Ultimately, if an after-market drug or device is found to be unsafe, the FDA can withdraw its marketing approval and require the manufacturer to withdraw/ recall it; the different classes of recall are summarized in Table 2 . 
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A U G U S T 2 0 1 6 : 3 9 9 -4 1 2 the Spring Fidelis and Riata leads, Liu et al. (76) commented that, despite "early identical patterns,"
reasons for the delay in the Riata lead recall compared with that of the Spring Fidelis were unclear, and speculated that it might be in part due to failures in the manufacturer-to-FDA reporting system.
Reliance on post-marketing surveillance to assess the experience with devices and device safety relies on the accuracy and quantity of data reported by manufacturers, which, as Kaszala and Ellenbogen (75) point out, "is not adjudicated by the Food and Drug
Administration." Post-market data are furthermore subject to underreporting of clinical events to the manufacturer by health care providers. In the words of Hauser (78), "our current passive post-marketing surveillance system fails to detect significant device defects before large patient populations have been exposed."
European law requires the manufacturer to report adverse events that they know about to the member state in which the CE mark was obtained (28) , and the lbsparrow@yahoo.com OR gvn@uw.edu.
